Susquehanna International Group’s Entrada Therapeutics TRDA Stock Holding History

Susquehanna International Group’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$256K	Buy	20,315 +4,954	+32%	+$56.8K	﹤0.01%	11215
2025 Q4	$158K	Buy	15,361 +3,853	+33%	+$32.5K	﹤0.01%	11121
2025 Q3	$66.7K	Sell	11,508 -25,307	-69%	-$148K	﹤0.01%	11759
2025 Q2	$247K	Buy	36,815 +4,855	+15%	+$39.1K	﹤0.01%	10770
2025 Q1	$289K	Buy	31,960 +19,028	+147%	+$237K	﹤0.01%	10142
2024 Q4	$224K	Buy	+12,932	New	+$234K	﹤0.01%	10474
2023 Q2	–	Sell	-196,513	Closed	-$2.85M	–	13153
2023 Q1	$2.85M	Buy	196,513 +84,716	+76%	+$1.13M	﹤0.01%	4435
2022 Q4	$1.51M	Buy	+111,797	New	+$1.96M	﹤0.01%	5262

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group's TRDA Position: Q1 2026 in Review

Susquehanna International Group increased its Entrada Therapeutics (TRDA) stake by 32% in Q1 2026, buying an estimated $56.8K and bringing the position to 20,315 shares worth $256K. The position accounts for ﹤0.01% of the portfolio, ranked #11215.

Susquehanna International Group first reported a position in TRDA in Q4 2022 and has held it in 8 quarters since. The position peaked at $2.85M in Q1 2023. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

Susquehanna International Group held 20,315 shares of Entrada Therapeutics worth $256K as of Q1 2026.
Susquehanna International Group bought 4,954 Entrada Therapeutics shares in Q1 2026, an estimated $56.8K.
Entrada Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11215 holding.
Susquehanna International Group first reported a position in Entrada Therapeutics in Q4 2022 and has held it in 8 quarters since.
Susquehanna International Group's Entrada Therapeutics position peaked at $2.85M in Q1 2023.
120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.